I lead the IMED Oncology unit and am responsible for research and early development from target selection to the initiation of pivotal trials.
I have over 17 years’ experience in drug discovery and development with a background as a Clinical Oncologist. I trained in medicine at Manchester and Cambridge Universities, was admitted to the Royal College of Physicians in 1992, and then trained in Clinical Oncology in London. I gained a Fellowship of the Royal College of Radiologists in 1997 and completed a PhD at the University of London involving translational work on a vascular-targeting agent.
I moved from medicine to industry in 2001, to Bristol-Myers Squibb where I held increasing levels of responsibility becoming Vice President for the Clinical Discovery Oncology & Immunology and Clinical Biomarkers groups.
I joined AstraZeneca in 2010 as Head of Oncology in the IMED Biotech Unit. Since joining, four programmes have moved into Phase 3 trials; and two are now approved in many countries around the world.
A critical focus for me in the drug development process is on ensuring quality target selection and engagement and selecting the right patients for treatment. This has led to the successful development of several novel treatments and I am proud to have played a part in their development, together with a great team at AstraZeneca. I am also passionate about developing the next generation of scientists and on improving diversity via personal mentorship.
In addition to my role at AstraZeneca, I co-lead the Cambridge Cancer Centre Onco-Innovation group, connecting Cambridge scientists to the biotech and pharmaceutical companies in the region; I am a Non-Executive on the Board of Horizon Discovery PLC, and on the Scientific Advisory Board of the ICR Cancer Research Centre of Excellence; and I serve on the AACR Finance Committee and the AACR Annual Meeting Scientific Program Committee.
Academy of Medical Sciences (AMS) Fellowship, 2018
Institute of Cancer Research Honorary degree (Doctor of Science, Medicine), 2017
Scrip Award, Best licensing deal of the year, 2013
Discovery, early development and patient selection strategy for osimertinib, the fastest ever developed drug from first patient dosed to approval in 2 years 8 months
Early development and patient selection strategy for olaparib, AstraZeneca’s first DDR medicine
Appointed to lead AstraZeneca IMED Oncology
Imaging the Effects of Vascular-Targeting Agents. In Vascular Targeted Therapies in Oncology
Galbraith, S.M. Imaging the Effects of Vascular-Targeting Agents. In Vascular Targeted Therapies in Oncology. D.W. Siemann (ed), Wiley & Sons, London, 277-304, 2005.
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumors: comparison of quantitative and semi-quantitative analysis
Galbraith S.M., Lodge M.A., Taylor N.J., Rustin G.J., Bentzen S., Stirling J.J., Padhani A.R. NMR Biomed. 2002 Apr; 15 (2): 132-42
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.